<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03364920</url>
  </required_header>
  <id_info>
    <org_study_id>SMPSSAP</org_study_id>
    <nct_id>NCT03364920</nct_id>
  </id_info>
  <brief_title>Serum Maresin-1 Predicts the Severity of Severe Acute Pancreatitis</brief_title>
  <official_title>Serum Maresin-1 Level Predicts the Disease Severity and Clinical Outcomes of Severe Acute Pancreatitis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weiqin Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective study about serum Maresin-1 level in different severe acute
      pancreatitis patients. The investigators want to study the correlation between the level of
      serum Maresin-1 and the severity of SAP, of course the clinical outcomes. The investigators
      want to find some biomarkers and strategy target drugs of severe acute pancreatitis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>mortality</measure>
    <time_frame>up to 28 days</time_frame>
    <description>The level of serum maresin-1 predicts the severity of severe acute pancreatitis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of MODS</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The level of serum maresin-1 predicts the severity of severe acute pancreatitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of IPN</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The level of serum maresin-1 predicts the severity of severe acute pancreatitis</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pancreatitis, Acute</condition>
  <arm_group>
    <arm_group_label>normal level of serum maresin-1</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>abnormal level of serum maresin-1</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        This study includes severe acute pancreatitis between 18ys and 75ys.Patients with disorder
        of glucolipide metabolism will be excluded. Alcoholic pancreatitis and HTG-AP patients will
        be also excluded. Patients will be divided into 2 groups according to their level of serum
        maresin-1.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Severe Acute Pancreatitis

          -  Biliary pancreatitis

          -  7 days of the onset

        Exclusion Criteria:

          -  Surgical patients

          -  Serious diseases and infection

          -  Alcoholic pancreatitis

          -  Hypertriglyceridemia pancreatitis

          -  Disorder of Glucolipide Metabolism：diabetes mellitus, hypertriglyceridemia, BMI＞30
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weiqin Li</last_name>
    <phone>13962531994</phone>
    <email>luyingying126@sina.cn</email>
  </overall_contact>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2017</study_first_submitted>
  <study_first_submitted_qc>December 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2017</study_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing University School of Medicine</investigator_affiliation>
    <investigator_full_name>Weiqin Li</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Maresin-1</keyword>
  <keyword>SAP</keyword>
  <keyword>IPN</keyword>
  <keyword>MODS</keyword>
  <keyword>Mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

